GSK · Healthcare
GSK PLC
Smart-money confidence
· 1 of 3 sources firing
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
38
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
◆ Next steps
Interested in GSK PLC? Here's what to do with it.
◇
Compare with other stocks
Sort 7,111 stocks by confidence, holders, or Congress signal
◈
Backtest the strategy
See how the model has done historically before you commit real money
✉
Get the weekly digest
One email on Sunday · what changed in the model this week
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$103.7B
Industry
Drug Manufacturers - General
Sector
Healthcare
Exchange
NYSE
About GSK PLC
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis,…
Who's behind the signal
Every informed buyer we can see on GSK, across all three feeds.
Hedge funds · 7
Point72 (Steve Cohen)
New position
Citadel Advisors
New position
D.E. Shaw & Co
New position
AQR Capital Management
Increased +16%
Tweedy Browne
Unchanged
Bridgewater Associates (Dalio)
Unchanged
+1 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trade history · 2
Every disclosed buy & sell on record — STOCK Act filings
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2017-06-15 | Patty Murray | Senate | SOLD | $1,001 - $15,000 |
| 2017-03-16 | Patty Murray | Senate | BOUGHT | $1,001 - $15,000 |
Not a model pick — but on our radar.
GSK PLC isn't in the top-10 model right now, but 7 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
7
Investors
3
New positions
1
Increasing
1
Decreasing
2
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.1×
% of portfolio
0.1%
Position change
NEW
0.1% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+16%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.2×
% of portfolio
0.3%
Position change
—
0.3% of Tweedy Browne's portfolio
Trust weight: 1.3×
% of portfolio
0.2%
Position change
—
0.2% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−33%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to GSK PLC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell GSK PLC or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime